Tag: ASX: CU6
Clarity and Nucleus RadioPharma scale up manufacturing for cancer treatment
Clarity Pharmaceuticals, a clinical-stage radiopharmaceutical company, has entered into a Master Services Agreement (MSA) and Clinical Manufacturing Agreement for the production of 67Cu-SAR-bisPSMA, a radiopharmaceutical treatment for prostate cancer.
Clarity Pharmaceuticals inks clinical supply agreement for prostate cancer imaging products
ASX-listed Clarity Pharmaceuticals has signed a Master Service Agreement and a Clinical Supply Agreement with Siemens Healthineers company PETNET Solutions Inc for the supply expansion of Clarity’s 64Cu SAR-bisPSMA, a diagnostic radiopharmaceutical product for prostate cancer imaging.
Featured Article
Why manufacturers are embracing AI-powered smart supply chains
Manufacturers are facing an increasingly volatile environment, where rapid changes in demand, supply chain disruptions, and continued cost pressures are transforming the way products are planned, made, and delivered.
